High Content Screening Market by Product & Services (Instrument (Cell Imaging, Analysis System), Consumables (Reagents & Assay Kits, Microplates), Software), Application (Drug Discovery & Development, Toxicology), End User - Global Forecast to 2030
The global high content screening market is anticipated to reach USD 2.19 billion in 2030 from USD 1.52 billion in 2025, with a significant CAGR of 7.5%. The market is growing at a significant CAGR owing to the innovations in high-resolution imaging, automation, and artificial intelligence (AI)-powered data analysis, which have significantly enhanced the efficiency and accuracy of HCS workflows. Advanced instruments equipped with high-speed fluorescence microscopy, confocal imaging, and real-time live-cell analysis enable deeper cellular insights, making them essential for drug discovery, toxicity screening, and disease research.
“Instruments dominated the products & service segment”
Based on product & service, the high content screening market is divided into instruments, consumables & accessories, software, and services. The instrument segment is further divided into high content imaging platforms, cell detection and analysis systems, and cell imaging systems. The rising demand for high-throughput screening and multiplexed assays in pharmaceutical and biotechnology research has accelerated the adoption of next-generation HCS systems. As research institutions and commercial laboratories seek to improve productivity and efficiency, the demand for cutting-edge HCS instruments is expected to drive significant market growth.
“Drug discovery & development application segment is anticipated to grow at a great pace”
The application segment is divided into drug discovery & development applications, toxicology, and basic research. The drug discovery & development application segment is further divided into primary screening and secondary screening, target identification and validation, compound profiling, and other drug discovery & development applications. The drug discovery & development dominated the market owing to the integration of artificial intelligence and automation in drug discovery workflows further enhances the efficiency of HCS, reducing time and costs associated with preclinical research. Furthermore, regulatory bodies emphasize early toxicity assessment, making HCS a preferred choice for evaluating drug safety before clinical trials. These factors collectively contribute to the dominant market share of drug discovery and development applications in the HCS market.
“Pharmaceutical & Biotechnology Companies dominated the segment”
Based on the end users, the market is segmented into pharmaceutical & biotechnology companies, academic & government institutes, and CROs & CDMOs. Pharmaceutical & biotechnology companies dominated the segment in 2024. The high share of pharmaceutical and biotechnology companies in the high content screening (HCS) market is primarily driven by their extensive use of HCS technologies in drug discovery and development. These companies rely on HCS for high-throughput screening, lead optimization, and toxicity assessment to accelerate the drug development process while ensuring safety and efficacy.
“North America: the largest share of the high content screening market”
The market is segmented by region into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. North America dominated the high content screening market in 2024 and is estimated to continue dominance during the forecast period. US leads the North American market, driven by the presence of leading academic & research institutions, and significant investment in biotechnology. The country’s focus on innovative medical research, personalized healthcare, and precision medicine further boosts its leadership in the market. European high content screening market is experiencing steady growth, supported by increasing research and development activities, especially in countries like Germany, the UK, and France.
In-depth interviews have been conducted with chief executive officers (CEOs), Directors, and other executives from various key organizations operating in the high content screening market.
The primary interviews conducted for this report can be categorized as follows:
Research Coverage:
High content screening market report is segmented based on products & services (instruments (high content imaging platforms, cell detection and analysis systems, and cell imaging systems), consumables & accessories (reagents & assay kits, microplates, and other consumables accessories), software, and services. Applications (drug discovery & development applications (primary screening and secondary screening, target identification and validation, compound profiling, and other drug discovery & development applications), toxicology, and basic research, end users (pharmaceutical & biotechnology companies, academic & government institutes, and CROs & CDMOs). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the high content screening market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products, key strategies, collaborations, partnerships, and agreements. New launches, collaborations and acquisitions, and recent developments associated with the high content screening market.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the high content screening and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
“Instruments dominated the products & service segment”
Based on product & service, the high content screening market is divided into instruments, consumables & accessories, software, and services. The instrument segment is further divided into high content imaging platforms, cell detection and analysis systems, and cell imaging systems. The rising demand for high-throughput screening and multiplexed assays in pharmaceutical and biotechnology research has accelerated the adoption of next-generation HCS systems. As research institutions and commercial laboratories seek to improve productivity and efficiency, the demand for cutting-edge HCS instruments is expected to drive significant market growth.
“Drug discovery & development application segment is anticipated to grow at a great pace”
The application segment is divided into drug discovery & development applications, toxicology, and basic research. The drug discovery & development application segment is further divided into primary screening and secondary screening, target identification and validation, compound profiling, and other drug discovery & development applications. The drug discovery & development dominated the market owing to the integration of artificial intelligence and automation in drug discovery workflows further enhances the efficiency of HCS, reducing time and costs associated with preclinical research. Furthermore, regulatory bodies emphasize early toxicity assessment, making HCS a preferred choice for evaluating drug safety before clinical trials. These factors collectively contribute to the dominant market share of drug discovery and development applications in the HCS market.
“Pharmaceutical & Biotechnology Companies dominated the segment”
Based on the end users, the market is segmented into pharmaceutical & biotechnology companies, academic & government institutes, and CROs & CDMOs. Pharmaceutical & biotechnology companies dominated the segment in 2024. The high share of pharmaceutical and biotechnology companies in the high content screening (HCS) market is primarily driven by their extensive use of HCS technologies in drug discovery and development. These companies rely on HCS for high-throughput screening, lead optimization, and toxicity assessment to accelerate the drug development process while ensuring safety and efficacy.
“North America: the largest share of the high content screening market”
The market is segmented by region into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. North America dominated the high content screening market in 2024 and is estimated to continue dominance during the forecast period. US leads the North American market, driven by the presence of leading academic & research institutions, and significant investment in biotechnology. The country’s focus on innovative medical research, personalized healthcare, and precision medicine further boosts its leadership in the market. European high content screening market is experiencing steady growth, supported by increasing research and development activities, especially in countries like Germany, the UK, and France.
In-depth interviews have been conducted with chief executive officers (CEOs), Directors, and other executives from various key organizations operating in the high content screening market.
The primary interviews conducted for this report can be categorized as follows:
- By Respondent: Tire 1- 55%, Tire 2-25%, Tire 3- 20%
- By Designation: Managers - 45%, CXO & Directors - 30%, and Executives - 25%
- By Region: North America -40%, Europe -25%, Asia-Pacific -25%, Latin America -5% and Middle East & Africa- 5%
Research Coverage:
High content screening market report is segmented based on products & services (instruments (high content imaging platforms, cell detection and analysis systems, and cell imaging systems), consumables & accessories (reagents & assay kits, microplates, and other consumables accessories), software, and services. Applications (drug discovery & development applications (primary screening and secondary screening, target identification and validation, compound profiling, and other drug discovery & development applications), toxicology, and basic research, end users (pharmaceutical & biotechnology companies, academic & government institutes, and CROs & CDMOs). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the high content screening market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products, key strategies, collaborations, partnerships, and agreements. New launches, collaborations and acquisitions, and recent developments associated with the high content screening market.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the high content screening and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
- Analysis of key drivers (Advancements in Imaging Technologies, Increased R&D projects, Adoption of High Throughput Screening, implementing organoid models in HCS), restraints (High Equipment and Reagents Costs, Complexity of Data Analysis), opportunities (Integration of AI and ML, Expansion into new applications) and Challenges (Lack of Standardized Protocol) influencing the growth of the market.
- Product Development/Innovation: Detailed insights on upcoming technologies in high content screening, research and development activities, and new product launches in the high content screening market.
- Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the high content screening market
- Competitive Assessment: In-depth assessment of market shares, growth strategies, and product & service offerings of leading players Danaher Corporation (US), Revvity, Inc. (US), BD (US), Carl Zeiss AG (Germany), Merck KGaA (Germany), and Thermo Fisher Scientific, Inc. (US), among others.
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY USED FOR THE STUDY
1.5 LIMITATIONS
1.6 MARKET STAKEHOLDERS
1.7 SUMMARY OF CHANGES
1.7.1 IMPACT OF AI/GENERATIVE AI
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
2.2 MARKET SIZE ESTIMATION
2.2.1 INSIGHTS FROM PRIMARY
2.2.2 SEGMENT ASSESSMENT METHODOLOGY
2.3 MARKET GROWTH RATE PROJECTIONS
2.4 DATA TRIANGULATION
2.5 RESEARCH ASSUMPTIONS
2.6 LIMITATIONS
2.7 RISK ASSESSMENT
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.2 RESTRAINTS
5.2.3 OPPORTUNITIES
5.2.4 CHALLENGES
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS BUSINESS
5.4 PRICING ANALYSIS
5.4.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT
5.4.2 AVERAGE SELLING PRICE TREND, BY REGION
5.5 SUPPLY CHAIN ANALYSIS
5.6 VALUE CHAIN ANALYSIS
5.7 ECOSYSTEM ANALYSIS
5.8 IMPACT OF AI/GEN AI
5.9 TECHNOLOGY ANALYSIS
5.9.1 KEY TECHNOLOGIES
5.9.2 COMPLEMENTARY TECHNOLOGIES
5.9.3 ADJACENT TECHNOLOGIES
5.10 PATENT ANALYSIS
5.11 KEY CONFERENCES & EVENTS 2025-2026
5.12 REGULATORY LANDSCAPE
5.12.1 REGULATORY SCENARIO
5.12.2 REGULATORY BODIES, GOVERNMENT AGENCIES & OTHER ORGANIZATIONS
5.13 PORTER’S FIVE FORCES ANALYSIS
5.13.1 THREAT OF NEW ENTRANTS
5.13.2 THREAT OF SUBSTITUTE
5.13.3 BARGAINING POWER OF SUPPLIERS
5.13.4 BARGAINING POWER OF BUYERS
5.13.5 INTENSITY OF COMPETITION RIVALRY
5.14 KEY STAKEHOLDERS AND BUYING CRITERIA
5.14.1 KEY STAKEHOLDERS IN THE BUYING PROCESS
5.14.2 BUYING CRITERIA FOR END USERS
5.15 INVESTMENT AND FUNDING SCENARIO
6 HIGH CONTENT SCREENING MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
6.1 INTRODUCTION
6.2 INSTRUMENTS
6.2.1 CELL IMAGING SYSTEMS
6.2.2 CELL DETECTION AND ANALYSIS SYSTEMS
6.2.3 HIGH CONTENT IMAGING PLATFORMS
6.3 CONSUMABLES & ACCESSORIES
6.3.1 REAGENTS & ASSAY KITS
6.3.2 MICROPLATES
6.3.3 OTHER CONSUMABLES & ACCESSORIES
6.4 SOFTWARE
6.5 SERVICES
Note 1: Other consumables & accessories segment is inclusive of cell culture accessories, microscopy accessories, and plate sealers.
Note 2: The above product & service segmentation is subject to change during research.
7 HIGH CONTENT SCREENING MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
7.1 INTRODUCTION
7.2 DRUG DISCOVERY AND DEVELOPMENT
7.2.1 TARGET IDENTIFICATION AND VALIDATION
7.2.2 PRIMARY SCREENING AND SECONDARY SCREENING
7.2.3 COMPOUND PROFILING
7.2.4 OTHER DRUG DISCOVERY AND DEVELOPMENT APPLICATIONS (IF ANY)
7.2 TOXICOLOGY
7.3 BASIC RESEARCH
Note 3: Basic research application segment is inclusive of cancer cell line screening, epigenetics, gene expression analysis, and stem cell research.
8 HIGH CONTENT SCREENING MARKET, BY END USER, 2022-2029 (USD MILLION)
8.1 INTRODUCTION
8.2 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES
8.3 ACADEMIC AND GOVERNMENT INSTITUTES
8.4 CONTRACT RESEARCH ORGANIZATIONS AND CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATIONS
9 HIGH CONTENT SCREENING MARKET, BY REGION, 2022-2029 (USD MILLION)
9.1 INTRODUCTION
9.2 NORTH AMERICA
9.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
9.2.2 US
9.2.3 CANADA
9.3 EUROPE
9.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
9.3.2 GERMANY
9.3.3 UK
9.3.4 FRANCE
9.3.5 ITALY
9.3.6 SPAIN
9.3.7 REST OF EUROPE
9.4 ASIA PACIFIC
9.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
9.4.2 JAPAN
9.4.3 CHINA
9.4.4 INDIA
9.4.5 SOUTH KOREA
9.4.6 AUSTRALIA
9.4.7 REST OF ASIA PACIFIC
9.5 LATIN AMERICA
9.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
9.5.2 BRAZIL
9.5.3 REST OF LATIN AMERICA
9.6 MIDDLE EAST
9.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST
9.6.2 GCC COUNTRIES
9.6.2.1 UNITED ARAB EMIRATES (UAE)
9.6.2.2 KINGDOM OF SAUDI ARABIA (KSA)
9.6.2.3 REST OF GCC COUNTRIES
12.6.3 REST OF MIDDLE EAST
9.7 AFRICA
9.7.1 MACROECONOMIC OUTLOOK FOR AFRICA
10 COMPETITIVE LANDSCAPE
10.1 INTRODUCTION
10.2 KEY PLAYERS STRATEGIES/ RIGHT TO WIN
10.3 REVENUE SHARE ANALYSIS (TOP 4-5 PLAYERS)
10.4 MARKET SHARE ANALYSIS (TOP 4-5 PLAYERS)
10.5 COMPANY EVALUATION MATRIX: KEY PLAYERS
10.5.1 STARS
10.5.2 EMERGING LEADERS
10.5.3 PERVASIVE PLAYERS
10.5.4 PARTICIPANTS
10.5.5 COMPANY FOOTPRINT: KEY PLAYERS
10.5.5.1 COMPANY FOOTPRINT
10.5.5.2 PRODUCT FOOTPRINT
10.5.5.3 SERVICE FOOTPRINT
10.5.5.4 APPLICATION FOOTPRINT
10.5.5.5 REGION FOOTPRINT
10.6 COMPANY EVALUATION MATRIX: START-UPS/SMES, 2023
10.6.1 PROGRESSIVE COMPANIES
10.6.2 RESPONSIVE COMPANIES
10.6.3 DYNAMIC COMPANIES
10.6.4 STARTING BLOCKS
10.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
10.6.5.1 DETAILED LIST OF KEY STARTUPS/ SMES
10.6.5.2 COMPETITIVE BENCHMARKING OF KEY STARTUPS/ SMES
10.7 COMPETITIVE SCENARIO
10.7.1 DEALS
10.7.2 OTHER DEVELOPMENTS
10.8 BRAND/ PRODUCT COMPARATIVE ANALYSIS
10.9 VENDOR VALUATION AND FINANCIAL METRICS OF THE RESIDUAL DNA TESTING MARKET
11 COMPANY PROFILES
11.1 KEY PLAYERS
11.1.1 DANAHER CORPORATION
11.1.2 REVVITY
11.1.3 BD
11.1.4 THERMO FISHER SCIENTIFIC INC.
11.1.5 AGILENT TECHNOLOGIES
11.1.6 MERCK KGAA
11.1.7 BIO-RAD LABORATORIES, INC.
11.1.8 NIKON INSTRUMENTS INC.
11.1.9 CARL ZEISS AG
11.1.10 SARTORIUS AG
11.1.11 YOKOGAWA ELECTRIC CORPORATION
11.1.12 TECAN TRADING AG
11.1.13 CORNING INCORPORATED
11.1.14 CHARLES RIVER LABORATORIES
11.2 OTHER PLAYERS
11.2.1 EVIDENT
11.2.2 PROMEGA CORPORATION
11.2.3 CREATIVE BIOLABS
11.2.4 SYSMEX CORPORATION
11.2.5 ENZO LIFE SCIENCES
11.2.6 STRATEDIGM CORPORATION
11.2.7 AKOYA BIOSCIENCES
11.2.8 SPHERE FLUIDICS
11.2.9 CREATIVE BIOSTRUCTURE
11.2.10 CREATIVE BIOARRAY
11.2.11 CELL SIGNALLING TECHNOLOGY
11.2.12 STANDARD BIOTOOLS
11.2.13 ARACELI BIOSCIENCES
12 APPENDIX
12.1 DISCUSSION GUIDE
12.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
12.3 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
12.4 AVAILABLE CUSTOMIZATIONS
12.5 RELATED REPORTS
12.6 AUTHOR DETAILS
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY USED FOR THE STUDY
1.5 LIMITATIONS
1.6 MARKET STAKEHOLDERS
1.7 SUMMARY OF CHANGES
1.7.1 IMPACT OF AI/GENERATIVE AI
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
2.2 MARKET SIZE ESTIMATION
2.2.1 INSIGHTS FROM PRIMARY
2.2.2 SEGMENT ASSESSMENT METHODOLOGY
2.3 MARKET GROWTH RATE PROJECTIONS
2.4 DATA TRIANGULATION
2.5 RESEARCH ASSUMPTIONS
2.6 LIMITATIONS
2.7 RISK ASSESSMENT
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.2 RESTRAINTS
5.2.3 OPPORTUNITIES
5.2.4 CHALLENGES
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS BUSINESS
5.4 PRICING ANALYSIS
5.4.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT
5.4.2 AVERAGE SELLING PRICE TREND, BY REGION
5.5 SUPPLY CHAIN ANALYSIS
5.6 VALUE CHAIN ANALYSIS
5.7 ECOSYSTEM ANALYSIS
5.8 IMPACT OF AI/GEN AI
5.9 TECHNOLOGY ANALYSIS
5.9.1 KEY TECHNOLOGIES
5.9.2 COMPLEMENTARY TECHNOLOGIES
5.9.3 ADJACENT TECHNOLOGIES
5.10 PATENT ANALYSIS
5.11 KEY CONFERENCES & EVENTS 2025-2026
5.12 REGULATORY LANDSCAPE
5.12.1 REGULATORY SCENARIO
5.12.2 REGULATORY BODIES, GOVERNMENT AGENCIES & OTHER ORGANIZATIONS
5.13 PORTER’S FIVE FORCES ANALYSIS
5.13.1 THREAT OF NEW ENTRANTS
5.13.2 THREAT OF SUBSTITUTE
5.13.3 BARGAINING POWER OF SUPPLIERS
5.13.4 BARGAINING POWER OF BUYERS
5.13.5 INTENSITY OF COMPETITION RIVALRY
5.14 KEY STAKEHOLDERS AND BUYING CRITERIA
5.14.1 KEY STAKEHOLDERS IN THE BUYING PROCESS
5.14.2 BUYING CRITERIA FOR END USERS
5.15 INVESTMENT AND FUNDING SCENARIO
6 HIGH CONTENT SCREENING MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
6.1 INTRODUCTION
6.2 INSTRUMENTS
6.2.1 CELL IMAGING SYSTEMS
6.2.2 CELL DETECTION AND ANALYSIS SYSTEMS
6.2.3 HIGH CONTENT IMAGING PLATFORMS
6.3 CONSUMABLES & ACCESSORIES
6.3.1 REAGENTS & ASSAY KITS
6.3.2 MICROPLATES
6.3.3 OTHER CONSUMABLES & ACCESSORIES
6.4 SOFTWARE
6.5 SERVICES
Note 1: Other consumables & accessories segment is inclusive of cell culture accessories, microscopy accessories, and plate sealers.
Note 2: The above product & service segmentation is subject to change during research.
7 HIGH CONTENT SCREENING MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
7.1 INTRODUCTION
7.2 DRUG DISCOVERY AND DEVELOPMENT
7.2.1 TARGET IDENTIFICATION AND VALIDATION
7.2.2 PRIMARY SCREENING AND SECONDARY SCREENING
7.2.3 COMPOUND PROFILING
7.2.4 OTHER DRUG DISCOVERY AND DEVELOPMENT APPLICATIONS (IF ANY)
7.2 TOXICOLOGY
7.3 BASIC RESEARCH
Note 3: Basic research application segment is inclusive of cancer cell line screening, epigenetics, gene expression analysis, and stem cell research.
8 HIGH CONTENT SCREENING MARKET, BY END USER, 2022-2029 (USD MILLION)
8.1 INTRODUCTION
8.2 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES
8.3 ACADEMIC AND GOVERNMENT INSTITUTES
8.4 CONTRACT RESEARCH ORGANIZATIONS AND CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATIONS
9 HIGH CONTENT SCREENING MARKET, BY REGION, 2022-2029 (USD MILLION)
9.1 INTRODUCTION
9.2 NORTH AMERICA
9.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
9.2.2 US
9.2.3 CANADA
9.3 EUROPE
9.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
9.3.2 GERMANY
9.3.3 UK
9.3.4 FRANCE
9.3.5 ITALY
9.3.6 SPAIN
9.3.7 REST OF EUROPE
9.4 ASIA PACIFIC
9.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
9.4.2 JAPAN
9.4.3 CHINA
9.4.4 INDIA
9.4.5 SOUTH KOREA
9.4.6 AUSTRALIA
9.4.7 REST OF ASIA PACIFIC
9.5 LATIN AMERICA
9.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
9.5.2 BRAZIL
9.5.3 REST OF LATIN AMERICA
9.6 MIDDLE EAST
9.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST
9.6.2 GCC COUNTRIES
9.6.2.1 UNITED ARAB EMIRATES (UAE)
9.6.2.2 KINGDOM OF SAUDI ARABIA (KSA)
9.6.2.3 REST OF GCC COUNTRIES
12.6.3 REST OF MIDDLE EAST
9.7 AFRICA
9.7.1 MACROECONOMIC OUTLOOK FOR AFRICA
10 COMPETITIVE LANDSCAPE
10.1 INTRODUCTION
10.2 KEY PLAYERS STRATEGIES/ RIGHT TO WIN
10.3 REVENUE SHARE ANALYSIS (TOP 4-5 PLAYERS)
10.4 MARKET SHARE ANALYSIS (TOP 4-5 PLAYERS)
10.5 COMPANY EVALUATION MATRIX: KEY PLAYERS
10.5.1 STARS
10.5.2 EMERGING LEADERS
10.5.3 PERVASIVE PLAYERS
10.5.4 PARTICIPANTS
10.5.5 COMPANY FOOTPRINT: KEY PLAYERS
10.5.5.1 COMPANY FOOTPRINT
10.5.5.2 PRODUCT FOOTPRINT
10.5.5.3 SERVICE FOOTPRINT
10.5.5.4 APPLICATION FOOTPRINT
10.5.5.5 REGION FOOTPRINT
10.6 COMPANY EVALUATION MATRIX: START-UPS/SMES, 2023
10.6.1 PROGRESSIVE COMPANIES
10.6.2 RESPONSIVE COMPANIES
10.6.3 DYNAMIC COMPANIES
10.6.4 STARTING BLOCKS
10.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
10.6.5.1 DETAILED LIST OF KEY STARTUPS/ SMES
10.6.5.2 COMPETITIVE BENCHMARKING OF KEY STARTUPS/ SMES
10.7 COMPETITIVE SCENARIO
10.7.1 DEALS
10.7.2 OTHER DEVELOPMENTS
10.8 BRAND/ PRODUCT COMPARATIVE ANALYSIS
10.9 VENDOR VALUATION AND FINANCIAL METRICS OF THE RESIDUAL DNA TESTING MARKET
11 COMPANY PROFILES
11.1 KEY PLAYERS
11.1.1 DANAHER CORPORATION
11.1.2 REVVITY
11.1.3 BD
11.1.4 THERMO FISHER SCIENTIFIC INC.
11.1.5 AGILENT TECHNOLOGIES
11.1.6 MERCK KGAA
11.1.7 BIO-RAD LABORATORIES, INC.
11.1.8 NIKON INSTRUMENTS INC.
11.1.9 CARL ZEISS AG
11.1.10 SARTORIUS AG
11.1.11 YOKOGAWA ELECTRIC CORPORATION
11.1.12 TECAN TRADING AG
11.1.13 CORNING INCORPORATED
11.1.14 CHARLES RIVER LABORATORIES
11.2 OTHER PLAYERS
11.2.1 EVIDENT
11.2.2 PROMEGA CORPORATION
11.2.3 CREATIVE BIOLABS
11.2.4 SYSMEX CORPORATION
11.2.5 ENZO LIFE SCIENCES
11.2.6 STRATEDIGM CORPORATION
11.2.7 AKOYA BIOSCIENCES
11.2.8 SPHERE FLUIDICS
11.2.9 CREATIVE BIOSTRUCTURE
11.2.10 CREATIVE BIOARRAY
11.2.11 CELL SIGNALLING TECHNOLOGY
11.2.12 STANDARD BIOTOOLS
11.2.13 ARACELI BIOSCIENCES
12 APPENDIX
12.1 DISCUSSION GUIDE
12.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
12.3 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
12.4 AVAILABLE CUSTOMIZATIONS
12.5 RELATED REPORTS
12.6 AUTHOR DETAILS
